BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jones DTW, Banito A, Grünewald TGP, Haber M, Jäger N, Kool M, Milde T, Molenaar JJ, Nabbi A, Pugh TJ, Schleiermacher G, Smith MA, Westermann F, Pfister SM. Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours. Nat Rev Cancer 2019;19:420-38. [DOI: 10.1038/s41568-019-0169-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 14.3] [Reference Citation Analysis]
Number Citing Articles
1 White CL, Jayasekara WSN, Picard D, Chen J, Watkins DN, Cain JE, Remke M, Gough DJ. A Sexually Dimorphic Role for STAT3 in Sonic Hedgehog Medulloblastoma. Cancers (Basel) 2019;11:E1702. [PMID: 31683879 DOI: 10.3390/cancers11111702] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
2 Hakar MH, Wood MD. Updates in Pediatric Glioma Pathology. Surg Pathol Clin 2020;13:801-16. [PMID: 33183734 DOI: 10.1016/j.path.2020.08.006] [Reference Citation Analysis]
3 Zahnreich S, Schmidberger H. Childhood Cancer: Occurrence, Treatment and Risk of Second Primary Malignancies. Cancers (Basel) 2021;13:2607. [PMID: 34073340 DOI: 10.3390/cancers13112607] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Liu Z, Xiao Z, Li M, Xiao Y, Wang X, He J, Li Y. Association Between Arg72Pro Polymorphism in TP53 and Malignant Abdominal Solid Tumor Risk in Hunan Children. Cancer Control 2021;28:10732748211004880. [PMID: 33759598 DOI: 10.1177/10732748211004880] [Reference Citation Analysis]
5 Fordham AM, Ekert PG, Fleuren EDG. Precision medicine and phosphoproteomics for the identification of novel targeted therapeutic avenues in sarcomas. Biochim Biophys Acta Rev Cancer 2021;:188613. [PMID: 34390800 DOI: 10.1016/j.bbcan.2021.188613] [Reference Citation Analysis]
6 Zafar A, Wang W, Liu G, Wang X, Xian W, McKeon F, Foster J, Zhou J, Zhang R. Molecular targeting therapies for neuroblastoma: Progress and challenges. Med Res Rev 2021;41:961-1021. [PMID: 33155698 DOI: 10.1002/med.21750] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
7 Soldozy S, Skaff A, Soldozy K, Sokolowski JD, Norat P, Yagmurlu K, Sharifi KA, Tvrdik P, Park MS, Kalani MYS, Jane JA, Syed HR. From Bench to Bedside, the Current State of Oncolytic Virotherapy in Pediatric Glioma. Neurosurgery 2020:nyaa247. [PMID: 32542365 DOI: 10.1093/neuros/nyaa247] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Barghi F, Shannon HE, Saadatzadeh MR, Bailey BJ, Riyahi N, Bijangi-Vishehsaraei K, Just M, Ferguson MJ, Pandya PH, Pollok KE. Precision Medicine Highlights Dysregulation of the CDK4/6 Cell Cycle Regulatory Pathway in Pediatric, Adolescents and Young Adult Sarcomas. Cancers (Basel) 2022;14:3611. [PMID: 35892870 DOI: 10.3390/cancers14153611] [Reference Citation Analysis]
9 Catanzaro G, Besharat ZM, Carai A, Jäger N, Splendiani E, Colin C, Po A, Chiacchiarini M, Citarella A, Gianno F, Cacchione A, Miele E, Diomedi Camassei F, Gessi M, Massimi L, Locatelli F, Jones DTW, Figarella-Branger D, Pfister SM, Mastronuzzi A, Giangaspero F, Ferretti E. MiR-1248: a new prognostic biomarker able to identify supratentorial hemispheric pediatric low-grade gliomas patients associated with progression. Biomark Res 2022;10:44. [PMID: 35715818 DOI: 10.1186/s40364-022-00389-x] [Reference Citation Analysis]
10 Manoharan N, O'Brien T. Childhood cancer: unique opportunities and inherent challenges. Med J Aust 2020;212:110-1. [PMID: 31981434 DOI: 10.5694/mja2.50487] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Ingley KM, Maleddu A, Grange FL, Gerrand C, Bleyer A, Yasmin E, Whelan J, Strauss SJ. Current approaches to management of bone sarcoma in adolescent and young adult patients. Pediatr Blood Cancer 2021;:e29442. [PMID: 34767314 DOI: 10.1002/pbc.29442] [Reference Citation Analysis]
12 Pearson ADJ, Rossig C, Lesa G, Diede SJ, Weiner S, Anderson J, Gray J, Geoerger B, Minard-Colin V, Marshall LV, Smith M, Sondel P, Bajars M, Baldazzi C, Barry E, Blackman S, Blanc P, Capdeville R, Caron H, Cole PD, Jiménez JC, Demolis P, Donoghue M, Elgadi M, Gajewski T, Galluzzo S, Ilaria R Jr, Jenkner A, Karres D, Kieran M, Ligas F, Lowy I, Meyers M, Oprea C, Peddareddigari VGR, Sterba J, Stockman PK, Suenaert P, Tabori U, van Tilburg C, Yancey T, Weigel B, Norga K, Reaman G, Vassal G. ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. Eur J Cancer 2020;127:52-66. [PMID: 31986450 DOI: 10.1016/j.ejca.2019.12.029] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
13 Chen Y, Miao L, Lin H, Zhuo Z, He J. The role of m6A modification in pediatric cancer. Biochim Biophys Acta Rev Cancer 2022;:188691. [PMID: 35122883 DOI: 10.1016/j.bbcan.2022.188691] [Reference Citation Analysis]
14 Musa J, Grünewald TGP. Interaction between somatic mutations and germline variants contributes to clinical heterogeneity in cancer. Mol Cell Oncol 2020;7:1682924. [PMID: 31993496 DOI: 10.1080/23723556.2019.1682924] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Grünewald TGP. [Integrative molecular pathology of cancer]. Pathologe 2020;41:67-9. [PMID: 33263807 DOI: 10.1007/s00292-020-00870-0] [Reference Citation Analysis]
16 Gout AM, Arunachalam S, Finkelstein DB, Zhang J. Data-driven approaches to advance research and clinical care for pediatric cancer. Biochim Biophys Acta Rev Cancer 2021;1876:188571. [PMID: 34051287 DOI: 10.1016/j.bbcan.2021.188571] [Reference Citation Analysis]
17 Zhang L, Zhao D, Wang Y, Zhang W, Zhang J, Fan J, Zhan Q, Chen J. Focal adhesion kinase (FAK) inhibitor-defactinib suppresses the malignant progression of human esophageal squamous cell carcinoma (ESCC) cells via effective blockade of PI3K/AKT axis and downstream molecular network. Mol Carcinog 2021;60:113-24. [PMID: 33283357 DOI: 10.1002/mc.23273] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
18 Noguera R, Álvaro Naranjo. Potential Molecular Players of the Tumor Microenvironment in Extracranial Pediatric Solid Tumors. Cancers (Basel) 2020;12:E2905. [PMID: 33050312 DOI: 10.3390/cancers12102905] [Reference Citation Analysis]
19 Peng L, Liang Y, Zhong X, Liang Z, Tian Y, Li S, Liang J, Wang R, Zhong Y, Shi Y, Zhang X. Aptamer-Conjugated Gold Nanoparticles Targeting Epidermal Growth Factor Receptor Variant III for the Treatment of Glioblastoma. Int J Nanomedicine 2020;15:1363-72. [PMID: 32184591 DOI: 10.2147/IJN.S238206] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
20 Blattner-Johnson M, Jones DTW, Pfaff E. Precision medicine in pediatric solid cancers. Semin Cancer Biol 2021:S1044-579X(21)00178-4. [PMID: 34116162 DOI: 10.1016/j.semcancer.2021.06.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
21 Wang J, Zhang L, Guo L, Que Y, Zhang Y, Sun F, Zhu J, Lu S, Huang J, Wu L, Cai R, Zhen Z, Zeng S, Zhang Y, Sun X. Irinotecan Plus Doxorubicin Hydrochloride Liposomes for Relapsed or Refractory Wilms Tumor. Front Oncol 2021;11:721564. [PMID: 34621673 DOI: 10.3389/fonc.2021.721564] [Reference Citation Analysis]
22 Madlener S, Gojo J. Liquid Biomarkers for Pediatric Brain Tumors: Biological Features, Advantages and Perspectives. J Pers Med 2020;10:E254. [PMID: 33260839 DOI: 10.3390/jpm10040254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Seton-Rogers S. Piles of profiles help identify vulnerabilities. Nat Rev Cancer 2020;20:73. [PMID: 31848465 DOI: 10.1038/s41568-019-0234-5] [Reference Citation Analysis]
24 McGill BC, Wakefield CE, Hetherington K, Munro LJ, Warby M, Lau L, Tyrrell V, Ziegler DS, O'Brien TA, Marshall GM, Malkin D, Hansford JR, Tucker KM, Vetsch J. "Balancing Expectations with Actual Realities": Conversations with Clinicians and Scientists in the First Year of a High-Risk Childhood Cancer Precision Medicine Trial. J Pers Med 2020;10:E9. [PMID: 32075154 DOI: 10.3390/jpm10010009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
25 Chen C, Dorado Garcia H, Scheer M, Henssen AG. Current and Future Treatment Strategies for Rhabdomyosarcoma. Front Oncol 2019;9:1458. [PMID: 31921698 DOI: 10.3389/fonc.2019.01458] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 10.7] [Reference Citation Analysis]
26 Cañete A. High-risk neuroblastoma: where do we go? Ann Oncol 2020;31:326-7. [PMID: 32067674 DOI: 10.1016/j.annonc.2019.12.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 Feng C, Li T, Xiao J, Wang J, Meng X, Niu H, Jiang B, Huang L, Deng X, Yan X, Wu D, Fang Y, Lin Y, Chen F, Wu X, Zhao X, Feng J. Tumor Microenvironment Profiling Identifies Prognostic Signatures and Suggests Immunotherapeutic Benefits in Neuroblastoma. Front Cell Dev Biol 2022;10:814836. [DOI: 10.3389/fcell.2022.814836] [Reference Citation Analysis]
28 Hansson K, Radke K, Aaltonen K, Saarela J, Mañas A, Sjölund J, Smith EM, Pietras K, Påhlman S, Wennerberg K, Gisselsson D, Bexell D. Therapeutic targeting of KSP in preclinical models of high-risk neuroblastoma. Sci Transl Med 2020;12:eaba4434. [PMID: 32967973 DOI: 10.1126/scitranslmed.aba4434] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
29 Tang F, Tie Y, Wei YQ, Tu CQ, Wei XW. Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials. Biochim Biophys Acta Rev Cancer 2021;1876:188606. [PMID: 34371128 DOI: 10.1016/j.bbcan.2021.188606] [Reference Citation Analysis]
30 Kazarian E, Marks A, Cui J, Darbinyan A, Tong E, Mueller S, Cha S, Aboian MS. Topographic correlates of driver mutations and endogenous gene expression in pediatric diffuse midline gliomas and hemispheric high-grade gliomas. Sci Rep 2021;11:14377. [PMID: 34257334 DOI: 10.1038/s41598-021-92943-0] [Reference Citation Analysis]
31 He J, Zhang Y, Zhu J, Tan H, Rössler J. Editorial: Molecular Diagnostics of Pediatric Cancer. Front Oncol 2021;11:777662. [PMID: 34708000 DOI: 10.3389/fonc.2021.777662] [Reference Citation Analysis]
32 Rovigatti U. The glycosphingolipid GD2 as an effective but enigmatic target of passive immunotherapy in children with aggressive neuroblastoma (HR-NBL). Cancer Lett 2021;503:220-30. [PMID: 33271265 DOI: 10.1016/j.canlet.2020.11.044] [Reference Citation Analysis]
33 Feng C, Xiang T, Yi Z, Meng X, Chu X, Huang G, Zhao X, Chen F, Xiong B, Feng J. A Deep-Learning Model With the Attention Mechanism Could Rigorously Predict Survivals in Neuroblastoma. Front Oncol 2021;11:653863. [PMID: 34336652 DOI: 10.3389/fonc.2021.653863] [Reference Citation Analysis]
34 Zirngibl F, Ivasko SM, Grunewald L, Klaus A, Schwiebert S, Ruf P, Lindhofer H, Astrahantseff K, Andersch L, Schulte JH, Lode HN, Eggert A, Anders K, Hundsdoerfer P, Künkele A. GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma. J Immunother Cancer 2021;9:e002923. [PMID: 34285106 DOI: 10.1136/jitc-2021-002923] [Reference Citation Analysis]
35 Stewart E. Orthotopic Implants in Mice. Methods Mol Biol 2021;2226:215-22. [PMID: 33326105 DOI: 10.1007/978-1-0716-1020-6_17] [Reference Citation Analysis]
36 Palmisani F, Kovar H, Kager L, Amann G, Metzelder M, Bergmann M. Systematic review of the immunological landscape of Wilms tumors. Mol Ther Oncolytics 2021;22:454-67. [PMID: 34553032 DOI: 10.1016/j.omto.2021.06.016] [Reference Citation Analysis]
37 Gargallo P, Bautista F, Juan-Ribelles A, Izquierdo E, Soriano A, de Rojas T, Escudero A, Lavarino C, Solano P, Hladun R, Rubio-San-Simón A, Martínez-Romera I, Calabria I, Olaciregui NG, Castañeda-Heredia A, de Álava E, Pérez-Martínez A, Astigarraga I, Patiño-García A, Alonso J, Fernández-Teijeiro A, Cañete A, Moreno L. Current status of precision medicine in pediatric oncology in Spain: a consensus report by the Spanish Society of Paediatric Haematology and Oncology (SEHOP). Clin Transl Oncol 2022;24:809-15. [PMID: 35152364 DOI: 10.1007/s12094-021-02759-7] [Reference Citation Analysis]
38 Gu Y, Hu X, Liu X, Cheng C, Chen K, Wu Y, Wu Z. MCM6 indicates adverse tumor features and poor outcomes and promotes G1/S cell cycle progression in neuroblastoma. BMC Cancer 2021;21:784. [PMID: 34233647 DOI: 10.1186/s12885-021-08344-z] [Reference Citation Analysis]
39 Reaman G, Stancato L, Vassal G, Maris JM. Crossing Oceans: Preclinical Collaboration to Improve Pediatric Drug Development. Am Soc Clin Oncol Educ Book 2020;40:1-8. [PMID: 32207673 DOI: 10.1200/EDBK_278893] [Reference Citation Analysis]
40 Schmelz K, Toedling J, Huska M, Cwikla MC, Kruetzfeldt LM, Proba J, Ambros PF, Ambros IM, Boral S, Lodrini M, Chen CY, Burkert M, Guergen D, Szymansky A, Astrahantseff K, Kuenkele A, Haase K, Fischer M, Deubzer HE, Hertwig F, Hundsdoerfer P, Henssen AG, Schwarz RF, Schulte JH, Eggert A. Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions. Nat Commun 2021;12:6804. [PMID: 34815394 DOI: 10.1038/s41467-021-26870-z] [Reference Citation Analysis]
41 Imle R, Kommoss FKF, Banito A. Preclinical In Vivo Modeling of Pediatric Sarcoma-Promises and Limitations. J Clin Med 2021;10:1578. [PMID: 33918045 DOI: 10.3390/jcm10081578] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Szymansky A, Kruetzfeldt LM, Heukamp LC, Hertwig F, Theissen J, Deubzer HE, Willing EM, Menon R, Fuchs S, Thole T, Schulte S, Schmelz K, Künkele A, Lang P, Fuchs J, Eggert A, Eckert C, Fischer M, Henssen AG, Rodriguez-Fos E, Schulte JH. Neuroblastoma Risk Assessment and Treatment Stratification with Hybrid Capture-Based Panel Sequencing. J Pers Med 2021;11:691. [PMID: 34442335 DOI: 10.3390/jpm11080691] [Reference Citation Analysis]
43 Wong M, Mayoh C, Lau LMS, Khuong-quang D, Pinese M, Kumar A, Barahona P, Wilkie EE, Sullivan P, Bowen-james R, Syed M, Martincorena I, Abascal F, Sherstyuk A, Bolanos NA, Baber J, Priestley P, Dolman MEM, Fleuren EDG, Gauthier M, Mould EVA, Gayevskiy V, Gifford AJ, Grebert-wade D, Strong PA, Manouvrier E, Warby M, Thomas DM, Kirk J, Tucker K, O’brien T, Alvaro F, Mccowage GB, Dalla-pozza L, Gottardo NG, Tapp H, Wood P, Khaw S, Hansford JR, Moore AS, Norris MD, Trahair TN, Lock RB, Tyrrell V, Haber M, Marshall GM, Ziegler DS, Ekert PG, Cowley MJ. Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. Nat Med 2020;26:1742-53. [DOI: 10.1038/s41591-020-1072-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 16.0] [Reference Citation Analysis]
44 Maspero M, Bentvelzen LG, Savenije MH, Guerreiro F, Seravalli E, Janssens GO, van den Berg CA, Philippens ME. Deep learning-based synthetic CT generation for paediatric brain MR-only photon and proton radiotherapy. Radiotherapy and Oncology 2020;153:197-204. [DOI: 10.1016/j.radonc.2020.09.029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
45 Król SK, Bębenek E, Dmoszyńska-Graniczka M, Sławińska-Brych A, Boryczka S, Stepulak A. Acetylenic Synthetic Betulin Derivatives Inhibit Akt and Erk Kinases Activity, Trigger Apoptosis and Suppress Proliferation of Neuroblastoma and Rhabdomyosarcoma Cell Lines. Int J Mol Sci 2021;22:12299. [PMID: 34830180 DOI: 10.3390/ijms222212299] [Reference Citation Analysis]
46 Segura MF, Soriano A, Roma J, Piskareva O, Jiménez C, Boloix A, Fletcher JI, Haber M, Gray JC, Cerdá-Alberich L, Martínez de Las Heras B, Cañete A, Gallego S, Moreno L. Methodological advances in the discovery of novel neuroblastoma therapeutics. Expert Opin Drug Discov 2021;:1-13. [PMID: 34807782 DOI: 10.1080/17460441.2022.2002297] [Reference Citation Analysis]
47 Stainczyk SA, Westermann F. Neuroblastoma-Telomere maintenance, deregulated signaling transduction and beyond. Int J Cancer 2021. [PMID: 34636058 DOI: 10.1002/ijc.33839] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Yang J, Zhou J, Li C, Wang S. Integrated analysis of the functions and prognostic values of RNA-binding proteins in neuroblastoma. PLoS One 2021;16:e0260876. [PMID: 34879089 DOI: 10.1371/journal.pone.0260876] [Reference Citation Analysis]
49 Garcia-Fabiani MB, Ventosa M, Comba A, Candolfi M, Nicola Candia AJ, Alghamri MS, Kadiyala P, Carney S, Faisal SM, Schwendeman A, Moon JJ, Scheetz L, Lahann J, Mauser A, Lowenstein PR, Castro MG. Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development. Expert Opin Investig Drugs 2020;29:659-84. [PMID: 32400216 DOI: 10.1080/13543784.2020.1768528] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
50 Gatto F, Milletti G, Carai A, Mastronuzzi A, Nazio F. Recent Advances in Understanding the Role of Autophagy in Paediatric Brain Tumours. Diagnostics (Basel) 2021;11:481. [PMID: 33803216 DOI: 10.3390/diagnostics11030481] [Reference Citation Analysis]
51 Jäger N. Bioinformatics workflows for clinical applications in precision oncology. Semin Cancer Biol 2021:S1044-579X(20)30279-0. [PMID: 33476720 DOI: 10.1016/j.semcancer.2020.12.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]